The Washington Research Foundation (WRF) has granted $6 million to a new initiative aimed at advancing late-stage preclinical development and first-in-human human clinical trials of novel therapeutics.
The foundation awarded $2 million to David Rawlings , MD, director of the Center for Immunity and Immunotherapies at Seattle Childrenβs Research Institute, for his work developing a treatment for a genetic disorder called X-linked agammaglobulinemia. Fred Hutch Cancer Centerβs Soheil Meshinchi, MD, PhD, an attending physician at Childrenβs, will use his $2 million WRF grant to develop a treatment for osteosarcoma, paving the way for future pediatric clinical studies at Childrenβs. Their teams are leveraging advanced gene and cell therapy techniques to create new treatments in critical areas of healthcare. Learn more:
bit.ly/3YB4joF